BioClinica Launches New eClinical CRO Partner Alliance Program
News Oct 24, 2015
BioClinica®, Inc. has announced the roll out of a new eClinical CRO Partner Alliance program, accelerating adoption of industry-leading eHealth solutions by CROs. The decision to redesign the CRO partner channel comes in response to growing demand for a premier eClinical technology platform that enables CROs and sponsors to conduct studies in an efficient and accelerated manner.
"We listened to our eClinical CRO customers, sponsors and the wider community to understand business pain-points, as well as the overall experience of working with technology product providers," said Mukhtar Ahmed, BioClinica's eClinical business segment president. "Based on feedback from senior clinical development, outsourcing and IT executives, it was evident a completely different partnering approach and philosophy was desired."
Ahmed explained, "Among their top priorities are CRO autonomy and product self-service capability, as well as access to a wealth of knowledge and best practices. They want this within a true partnership − one with strategic business alignment, collaboration and accountability for service delivery and product quality."
To address this need, BioClinica's eClinical CRO Partner Alliance is flexible and built around each partner's unique needs and business model. BioClinica Director of CRO Business Development, Jason Attanucci said, "Our CRO partners receive flexible licensing, preferred pricing and incentives along with service and quality assurance benefits, which ultimately help them reach sponsor customers previously inaccessible."
Dedicated CRO relationship managers work closely with each partner to create a tailored eHealth solution offering. Partners may leverage certification and services in the BioClinica platform or individual solutions to achieve unique financial benefits in areas including:
• Randomization, trial supply management and forecasting with predictive analytics
• Intelligent risk-based monitoring
• Clinical trial management, operations and payments
• Electronic data capture, comprehensive data management, and clinical operations support
"The breadth of services and technology available through our eClinical CRO Partner Alliance has never been seen before in this industry," Attanucci said. Partners are able to leverage BioClinica's extensive knowledge gained in providing study management, risk-based monitoring, data capture, randomization and trial supply management technology and supporting services for thousands of clinical trials globally. "We've already seen tremendous uptake in our Partner Alliance from CROs around the world, and we will begin announcing new members in coming weeks."
In addition to BioClinica's world-class data, regulatory, reporting and analytics technology, CRO partners can tap into unique product innovation found within the eHealth App xChange™. The App xChange enables access to a growing list of consumer applications, such as electronic health records, patient diaries, adherence, safety utilities, questionnaires, eTMF, and other patient-centric apps in a secure and scalable way through BioClinica's regulatory compliant eHealth Cloud™ architecture.
To kick off the new CRO Partner Alliance, BioClinica invites prospective partners to stop by its exhibit at the Partnerships in Clinical Trials conference in Hamburg, Germany on November 18 and 19 to learn about partnering opportunities and see product demonstrations. BioClinica's Global Product Development Senior Vice President, Andrew Masters, will speak on an expert panel on RBM best practices and lessons learned.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018